Skip to main content
Top
Published in: Indian Journal of Surgery 5/2015

01-10-2015 | Original Article

Diagnosis, Preoperative Evaluation, and Assessment of Resectability of Pancreatic and Periampullary Cancer

Authors: Ashish Verma, Sunit Shukla, Nimisha Verma

Published in: Indian Journal of Surgery | Issue 5/2015

Login to get access

Abstract

Periampullary region encircles a radius of 2 cm around the ampulla of Vater; accordingly, four distinct neoplasias with overlapping imaging features originate in the region. Each of these lesions has a different long-term prognosis; hence, imaging evaluation to characterize the lesion is important. Further certain specific features pertaining to the vascular invasion and systemic spread may decide about the treatment as well as surgical approach. An understanding of the advances in imaging and image processing technology as well as in the methods of image acquisition, for the purpose, is quite relevant towards etching out a rational pre-treatment evaluation protocol. Further, an evidence-based decision as to the choice of optimum modality for answering specific clinical question is of prime importance in achieving a reasonable post-treatment outcome. Pancreatic adenocarcinoma is the fourth most common cancer and a malignancy with one of the least 5-year survival rates (ranging from 6.8 to 15 % depending on peripancreatic extensions, dropping to 1.8 % for metastatic disease). A survival rate of 15–27 % can be achieved if the lesion is resectable but unfortunately, only 10–15 % of patients are eligible for resection. Cystic tumors of pancreas are a rarer variety of pancreatic neoplasia (5–15 % of pancreatic cysts and 1 % of all pancreatic cancers) which have a much better outcome and chances of resection. Being mostly incidentalomas, a timely differentiation of this lesion from the much more common pseudocyst (which would mandate a medical management and a different surgical protocol) is the key for curability. Lastly, the neuroendocrine tumors of pancreas are equally rare (1 % of all pancreatic tumors), but importantly due to associated clinical syndromes and their capability to metastasize early in the course of disease, a timely detection may hence be the key for successful treatment of these lesions. Imaging plays a vital role in the initial detection and characterization as well as in determination of resectability of each of these pancreatic neoplasias. Further, the differentiation of pancreatic head tumors from other periampullary neoplasias is important; the fact that most recurrences are as a result of surgical intervention in an otherwise inoperable disease while most treatment failures are due to improper characterization of the lesion is notable.
Literature
1.
go back to reference Kim SY, Lee JM, Kim SH, Shin KS, Kim YJ, An SK et al (2006) Macrocystic neoplasms of the pancreas: CT differentiation of serous oligocystic adenoma from mucinous cystadenoma and intraductal papillary mucinous tumor. AJR Am J Roentgenol 187:1192–1198PubMedCrossRef Kim SY, Lee JM, Kim SH, Shin KS, Kim YJ, An SK et al (2006) Macrocystic neoplasms of the pancreas: CT differentiation of serous oligocystic adenoma from mucinous cystadenoma and intraductal papillary mucinous tumor. AJR Am J Roentgenol 187:1192–1198PubMedCrossRef
2.
go back to reference Park MS, Kim KW, Lim JS, Lee JH, Kim JH, Kim SY et al (2005) Unusual cystic neoplasms in the pancreas: radiologicpathologic correlation. J Comput Assist Tomogr 29:610–616PubMedCrossRef Park MS, Kim KW, Lim JS, Lee JH, Kim JH, Kim SY et al (2005) Unusual cystic neoplasms in the pancreas: radiologicpathologic correlation. J Comput Assist Tomogr 29:610–616PubMedCrossRef
3.
go back to reference Irie H, Honda H, Aibe H, Kuroiwa T, Yoshimitsu K, Shinozaki K et al (2000) MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas. AJR Am J Roentgenol 174:1403–1408PubMedCrossRef Irie H, Honda H, Aibe H, Kuroiwa T, Yoshimitsu K, Shinozaki K et al (2000) MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas. AJR Am J Roentgenol 174:1403–1408PubMedCrossRef
4.
go back to reference Song SJ, Lee JM, Kim YJ, Kim SH, Lee JY, Han JK et al (2007) Differentiation of intraductal papillary mucinous neoplasms from other pancreatic cystic masses: comparison of multirowdetector CT and MR imaging using ROC analysis. J Magn Reson Imaging 26:86–93PubMedCrossRef Song SJ, Lee JM, Kim YJ, Kim SH, Lee JY, Han JK et al (2007) Differentiation of intraductal papillary mucinous neoplasms from other pancreatic cystic masses: comparison of multirowdetector CT and MR imaging using ROC analysis. J Magn Reson Imaging 26:86–93PubMedCrossRef
5.
go back to reference Sahani DV, Kadavigere R, Saokar A, Fernandez-del Castillo C, Brugge WR, Hahn PF (2005) Cystic pancreatic lesions: a simple imaging-based classification system for guiding management. Radiographics 25:1471–1484PubMedCrossRef Sahani DV, Kadavigere R, Saokar A, Fernandez-del Castillo C, Brugge WR, Hahn PF (2005) Cystic pancreatic lesions: a simple imaging-based classification system for guiding management. Radiographics 25:1471–1484PubMedCrossRef
6.
go back to reference Cho H-W, Choi J-Y, Kim M-J, Park M-S, Lim JS, Chung YE, Kim KW (2011) Pancreatic tumors: emphasis on CT findings and pathologic classification. KJR 12(6):731–739CrossRef Cho H-W, Choi J-Y, Kim M-J, Park M-S, Lim JS, Chung YE, Kim KW (2011) Pancreatic tumors: emphasis on CT findings and pathologic classification. KJR 12(6):731–739CrossRef
7.
go back to reference Nikolaidis P, Hammond NA, Day K, Yaghmai V, Wood CG 3rd, Mosbach DS, Harmath CB, Taffel MT, Horowitz JM, Berggruen SM, Miller FH (2014) Imaging features of benign and malignant ampullary and periampullary lesions. Radiographics 34(3):624–641PubMedCrossRef Nikolaidis P, Hammond NA, Day K, Yaghmai V, Wood CG 3rd, Mosbach DS, Harmath CB, Taffel MT, Horowitz JM, Berggruen SM, Miller FH (2014) Imaging features of benign and malignant ampullary and periampullary lesions. Radiographics 34(3):624–641PubMedCrossRef
8.
go back to reference Wiersema MJ, Wiersema LM (1996) Endosonography guided celiac plexus neurolysis. Gastrointest Endosc 44:656–662PubMedCrossRef Wiersema MJ, Wiersema LM (1996) Endosonography guided celiac plexus neurolysis. Gastrointest Endosc 44:656–662PubMedCrossRef
9.
go back to reference Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, Carlos BM, Warner DO (2004) Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer—a randomized controlled trial. JAMA 291(9):1092–1099PubMedCrossRef Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, Carlos BM, Warner DO (2004) Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer—a randomized controlled trial. JAMA 291(9):1092–1099PubMedCrossRef
10.
go back to reference Wyse JM, Chen YI, Sahai AV (2014) Celiac plexus neurolysis in the management of unresectable pancreatic cancer: when and how? World J Gastroenterol 20(9):2186–2192PubMedPubMedCentralCrossRef Wyse JM, Chen YI, Sahai AV (2014) Celiac plexus neurolysis in the management of unresectable pancreatic cancer: when and how? World J Gastroenterol 20(9):2186–2192PubMedPubMedCentralCrossRef
11.
go back to reference Papadopoulos D, Kostopanagiotou G, Batistaki C (2013) Bilateral thoracic splanchnic nerve radiofrequency thermocoagulation for the management of end-stage pancreatic abdominal cancer pain. Pain Physician 16:125–133PubMed Papadopoulos D, Kostopanagiotou G, Batistaki C (2013) Bilateral thoracic splanchnic nerve radiofrequency thermocoagulation for the management of end-stage pancreatic abdominal cancer pain. Pain Physician 16:125–133PubMed
12.
13.
go back to reference Arnold LD, Patel AV, Yan Y, Jacobs EJ, Thun MJ, Calle EE, Colditz GA (2009) Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev 18(9):2397–2405PubMedPubMedCentralCrossRef Arnold LD, Patel AV, Yan Y, Jacobs EJ, Thun MJ, Calle EE, Colditz GA (2009) Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev 18(9):2397–2405PubMedPubMedCentralCrossRef
14.
go back to reference Simard EP, Ward EM, Siegel R, Jemal A (2012) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62(2):118–128PubMedCrossRef Simard EP, Ward EM, Siegel R, Jemal A (2012) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62(2):118–128PubMedCrossRef
15.
go back to reference Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758–2765PubMedCrossRef Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758–2765PubMedCrossRef
16.
go back to reference Visser BC, Ma Y, Zak Y, Poultsides GA, Norton JA, Rhoads KF (2012) Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxford) 14(8):539–547CrossRef Visser BC, Ma Y, Zak Y, Poultsides GA, Norton JA, Rhoads KF (2012) Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxford) 14(8):539–547CrossRef
17.
go back to reference Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CH (2014) Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol 40(7):794–804PubMedCrossRef Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CH (2014) Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol 40(7):794–804PubMedCrossRef
18.
go back to reference Rösch T, Braig C, Gain T, Feuerbach S, Siewert JR, Schusdziarra V, Classen M (1992) Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. Gastroenterology 102(1):188–199PubMed Rösch T, Braig C, Gain T, Feuerbach S, Siewert JR, Schusdziarra V, Classen M (1992) Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. Gastroenterology 102(1):188–199PubMed
19.
go back to reference Varadarajulu S, Wallace MB (2004) Applications of endoscopic ultrasonography in pancreatic cancer. Cancer Control 11(1):15–22PubMed Varadarajulu S, Wallace MB (2004) Applications of endoscopic ultrasonography in pancreatic cancer. Cancer Control 11(1):15–22PubMed
20.
go back to reference Fuhrman GM, Charnsangavej C, Abbruzzese JL, Cleary KR, Martin RG, Fenoglio CJ, Evans DB (1994) Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 167(1):104–111PubMedCrossRef Fuhrman GM, Charnsangavej C, Abbruzzese JL, Cleary KR, Martin RG, Fenoglio CJ, Evans DB (1994) Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 167(1):104–111PubMedCrossRef
21.
go back to reference Horton KM, Fishman EK (2002) Adenocarcinoma of the pancreas: CT imaging. Radiol Clin N Am 40(6):1263–1272PubMedCrossRef Horton KM, Fishman EK (2002) Adenocarcinoma of the pancreas: CT imaging. Radiol Clin N Am 40(6):1263–1272PubMedCrossRef
22.
go back to reference House MG, Yeo CJ, Cameron JL, Campbell KA, Schulick RD, Leach SD, Hruban RH, Horton KM, Fishman EK, Lillemoe KD (2004) Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 8(3):280–288PubMedCrossRef House MG, Yeo CJ, Cameron JL, Campbell KA, Schulick RD, Leach SD, Hruban RH, Horton KM, Fishman EK, Lillemoe KD (2004) Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 8(3):280–288PubMedCrossRef
23.
go back to reference Klauss M, Schöbinger M, Wolf I, Werner J, Meinzer HP, Kauczor HU, Grenacher L (2009) Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol 15(46):5827–5832PubMedPubMedCentralCrossRef Klauss M, Schöbinger M, Wolf I, Werner J, Meinzer HP, Kauczor HU, Grenacher L (2009) Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol 15(46):5827–5832PubMedPubMedCentralCrossRef
24.
go back to reference Günter S, Siveke JT, Eckel F, Schmid RM (2005) Pancreatic cancer: basic and clinical aspects. Gastroenterology 128:1606–1625CrossRef Günter S, Siveke JT, Eckel F, Schmid RM (2005) Pancreatic cancer: basic and clinical aspects. Gastroenterology 128:1606–1625CrossRef
25.
go back to reference Schima W, Ba-Ssalamah A, Goetzinger P, Scharitzer M, Koelblinger C (2007) State-of-the-art magnetic resonance imaging of pancreatic cancer. Top Magn Reson Imaging 18(6):421–429PubMedCrossRef Schima W, Ba-Ssalamah A, Goetzinger P, Scharitzer M, Koelblinger C (2007) State-of-the-art magnetic resonance imaging of pancreatic cancer. Top Magn Reson Imaging 18(6):421–429PubMedCrossRef
26.
go back to reference Nallamothu G, Hilden K, Adler DG (2011) Endoscopic retrograde cholangiopancreatography for non-gastroenterologists: what you need to know. Hosp Pract (1995) 39(2):70–80CrossRef Nallamothu G, Hilden K, Adler DG (2011) Endoscopic retrograde cholangiopancreatography for non-gastroenterologists: what you need to know. Hosp Pract (1995) 39(2):70–80CrossRef
27.
go back to reference Tirkes T, Sandrasegaran K, Sanyal R, Sherman S, Schmidt CM, Cote GA, Akisik F (2013) Secretin-enhanced MR cholangiopancreatography: spectrum of findings. Radiographics 33(7):1889–1906PubMedCrossRef Tirkes T, Sandrasegaran K, Sanyal R, Sherman S, Schmidt CM, Cote GA, Akisik F (2013) Secretin-enhanced MR cholangiopancreatography: spectrum of findings. Radiographics 33(7):1889–1906PubMedCrossRef
28.
go back to reference Warshaw AL, Gu ZY, Wittenberg J, Waltman AC (1990) Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 125(2):230–233PubMedCrossRef Warshaw AL, Gu ZY, Wittenberg J, Waltman AC (1990) Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 125(2):230–233PubMedCrossRef
29.
go back to reference Andersson R, Vagianos CE, Williamson RC (2004) Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 6(1):5–12CrossRef Andersson R, Vagianos CE, Williamson RC (2004) Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 6(1):5–12CrossRef
30.
go back to reference Varadachary GR, Wolff RA, Crane CH et al (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487–3495CrossRef Varadachary GR, Wolff RA, Crane CH et al (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487–3495CrossRef
Metadata
Title
Diagnosis, Preoperative Evaluation, and Assessment of Resectability of Pancreatic and Periampullary Cancer
Authors
Ashish Verma
Sunit Shukla
Nimisha Verma
Publication date
01-10-2015
Publisher
Springer India
Published in
Indian Journal of Surgery / Issue 5/2015
Print ISSN: 0972-2068
Electronic ISSN: 0973-9793
DOI
https://doi.org/10.1007/s12262-015-1370-0

Other articles of this Issue 5/2015

Indian Journal of Surgery 5/2015 Go to the issue

Editorial

Foreword